Company Overview - Contineum Therapeutics, Inc. (CTNM) is part of the Medical group, which consists of 928 companies and is currently ranked 10 in the Zacks Sector Rank [2] - CTNM has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Metrics - Over the past three months, the Zacks Consensus Estimate for CTNM's full-year earnings has increased by 11.5%, reflecting improved analyst sentiment [4] - Year-to-date, CTNM has achieved a return of approximately 33.1%, significantly outperforming the average return of 3.5% for Medical companies [4] Industry Comparison - CTNM belongs to the Medical - Biomedical and Genetics industry, which includes 449 stocks and is currently ranked 90 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 19.4% this year, indicating that CTNM is performing well within its specific industry [6] Additional Comparisons - Another Medical stock, Quest Diagnostics (DGX), has returned 6.7% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Quest Diagnostics is part of the Medical - Outpatient and Home Healthcare industry, which has a lower year-to-date return of 3.6% and is ranked 196 [7]
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?